Literature DB >> 2917583

Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments.

G Barzen1, A C Mayr, M Langer, R Becker, M Cordes, C Zwicker, K Koppenhagen, R Felix.   

Abstract

Radioimmunoscintigraphy (RIS) with 131I labeled OC-125 F(ab')2 monoclonal antibody fragments was prospectively studied in 43 women for primary diagnosis and follow up of ovarian cancer. Total body planar photoscans with a scintillation camera were performed one to seven days after antibody application and results were compared with operation and or CT examination. By the region of interest technique the tumor to non tumor tissue ratio (T/N) was calculated in vivo. Sensitivity in primary diagnosis was 100% (10/10), specificity 33% (1/3). For local recurrency, sensitivity was 86% (19/22), for metastatic loci 80% (17/21). Specificity was 75% and 50%. T/N ratio was in the rage from 1.3 to 2.8. Sensitivity for ovarian cancer is high in primary diagnosis and follow up. By the region of interest technique it is possible to detect small recurrencies and to presume peritoneal carcinosis. Antibody accumulations in diseases different from ovarian cancer however diminish specificity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917583     DOI: 10.1007/BF00253598

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  20 in total

1.  The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies.

Authors:  D PRESSMAN; L KORNGOLD
Journal:  Cancer       Date:  1953-05       Impact factor: 6.860

2.  Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunohistochemistry.

Authors:  H J Biersack; A Bockisch; P Oehr; A Knoblich; J Hartlapp; H Biltz; N Jaeger; O Bellmann; J Vogel; B Björklund
Journal:  Nuklearmedizin       Date:  1986-10       Impact factor: 1.379

3.  Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen.

Authors:  D M Goldenberg; E E Kim; F H DeLand; S Bennett; F J Primus
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

4.  Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.

Authors:  F Pansini; A Bellinazzi; V Rainaldi; M Santoiemma; B Lenzi; M Jacobs; G Mollica; B Bagni
Journal:  Gynecol Obstet Invest       Date:  1986       Impact factor: 2.031

5.  Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies.

Authors:  F H DeLand; D M Goldenberg
Journal:  Semin Nucl Med       Date:  1985-01       Impact factor: 4.446

6.  Radionuclide imaging of ovarian tumours with 123I-labelled monoclonal antibody (NDOG2) directed against placental alkaline phosphatase.

Authors:  J O Davies; E R Davies; K Howe; P C Jackson; E M Pitcher; C S Sadowski; G M Stirrat; C A Sunderland
Journal:  Br J Obstet Gynaecol       Date:  1985-03

7.  Localisation of malignant germ-cell tumours by external scanning after injection of radiolabelled anti-alpha-fetoprotein.

Authors:  A K Halsall; D S Fairweather; A R Bradwell; J C Blackburn; P W Dykes; A Howell; A Reeder; K R Hine
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-10

8.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

9.  In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments.

Authors:  F Buchegger; S E Halpern; R M Sutherland; M Schreyer; J P Mach
Journal:  Nuklearmedizin       Date:  1986-12       Impact factor: 1.379

10.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

View more
  6 in total

Review 1.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

2.  A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer.

Authors:  H Kobayashi; H Sakahara; T Saga; M Hosono; M Shirato; H Kanda; K Ishibashi; T Watanabe; K Endo; I Ishiwata
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

3.  Correlative imaging study in the diagnosis of ovarian cancer recurrences. The INSERM Research Network (Nantes, Rennes, Reims, Villejuif, Saclay), France.

Authors:  P Peltier; K Wiharto; J P Dutin; J F Chatal; P Bourguet; J C Liehn; J P Vuillez; J Y Hérry; A Loboguerrero
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  MUC16 as a novel target for cancer therapy.

Authors:  Abhijit Aithal; Sanchita Rauth; Prakash Kshirsagar; Ashu Shah; Imayavaramban Lakshmanan; Wade M Junker; Maneesh Jain; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Expert Opin Ther Targets       Date:  2018-07-26       Impact factor: 6.902

5.  Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences.

Authors:  C Alexander; C E Villena-Heinsen; L Trampert; S Lung-Kurt; E Oberhausen; C M Kirsch; W Schmidt
Journal:  Eur J Nucl Med       Date:  1995-07

6.  Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts.

Authors:  Chung-Wein Lee; Lili Guo; Daniela Matei; Keith Stantz
Journal:  J Biotechnol Biomater       Date:  2015-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.